Solid Biosciences (SLDB) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, in a virtual-only format, allowing global participation and equal shareholder rights as an in-person meeting.

• Shareholders will vote on director elections, auditor ratification, an amendment to increase authorized shares, and executive compensation, among other matters.

• Proxy materials are distributed primarily online to reduce environmental impact and costs, with paper copies available upon request.

Voting matters and shareholder proposals

• Proposals include electing three Class II directors, ratifying Ilan Ganot as a Class I director, ratifying PricewaterhouseCoopers LLP as auditor, amending the Certificate of Incorporation to double authorized common shares, and an advisory vote on executive compensation.

• The board unanimously recommends voting FOR all proposals.

• Voting can be done online, by phone, mail, or during the virtual meeting; a majority of shares is required for quorum.

Board of directors and corporate governance

• The board is divided into three classes with staggered three-year terms; current nominees have extensive experience in biotech, finance, and regulatory affairs.

• The board maintains a majority of independent directors and separates the roles of CEO and chairman.

• Four standing committees (audit, compensation, nominating and governance, clinical) oversee key areas, each with independent members.

• Corporate governance guidelines and a code of conduct are in place, with annual board self-evaluations and director orientation.